China SXT Pharmaceuticals, Inc. (SXTC): Financials
Fiscal year ended March 31, 2026
Income statement, cash flow and balance sheet figures for China SXT Pharmaceuticals, Inc. (SXTC), read directly from the XBRL data the company files with the SEC. Over the most recent fiscal year the company reported $1.1M of revenue, down 34.6% year over year. Net loss was $6.2M, or $-9.13 per diluted share. Gross margin stood at 21.9%.
Against the current share price, SXTC trades at 1.0 times trailing revenue.
10 fiscal years of history are available, back to 2017.
Frequently asked questions
How much revenue does SXTC make?
China SXT Pharmaceuticals, Inc. reported $1.1M of revenue over the most recent fiscal year, for the period ended March 31, 2026. That is down 34.6% from the same period a year earlier.
Is SXTC profitable?
China SXT Pharmaceuticals, Inc. was unprofitable over the most recent fiscal year, with a net loss of $6.2M.
Where does this financial data come from?
Every figure on this page is read from the company's own SEC 10-Q and 10-K filings. Nothing is estimated by a third party. Quarterly figures a company does not file separately (most commonly the fourth quarter) are derived by subtracting the reported year-to-date quarters from the full fiscal year, and are labelled as derived.
What is the difference between quarterly, annual and TTM?
Quarterly shows each three-month fiscal period on its own. Annual shows the full fiscal year as filed in the 10-K. TTM (trailing twelve months) sums the last four reported quarters, which is the most current annualised view between 10-K filings.